|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||4.0200 - 4.4700|
|52 Week Range||0.9125 - 5.6500|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The allure of investing in marijuana penny stocks can be very strong. Every investor has dreams of investing a couple thousand dollars in a penny stock, watching it go to $100 per share, and making millions of dollars. I know that I sure do.Even more tempting are penny stocks of companies that are in the marijuana industry. In this rapidly boom industry, it seems reasonable to assume that there are some hidden gems out there.But you need to be careful when investing in low prices stocks because most of these companies will not survive. After all, there is a reason why they trade at such low prices.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Defense Stocks to Buy to Fortify Your Portfolio The following seven marijuana penny stocks are worth considering for different reasons. These are not recommendations. I just want to give you some insights to help you make a decisions. Emerald Health Therapeutics Inc. (EMHTF) Click to EnlargeEmerald Health Therapeutics (OTCMKTS:EMHTF) is a pharmaceutical company that produces and sells cannabis products.I think that there will soon be a price war in the cannabis industry. That is because investors are starting to realize that the costs savings of growing cannabis outside outweigh any benefits that growing indoors or in greenhouses.The large growers like Tilray (NASDAQ:TLRY), Cronos (NASDAQ:CRON), Aphria (NYSE:APHA) and Aurora (NYSE:ACB) primarily grow indoors or in greenhouses. They may have difficult time competing with the outdoors growers that can offer their customers much lower prices.Emerald Health grows in greenhouses but they are moving into outdoor growing. The company just received it cultivation license from Health Canada for a 12-acre outside grow area. This early move into outside growing could be a very bullish dynamic.Technically, this could be a logical place to buy EMHTF. It is a level that was support in December. It is also very oversold. 48North Cannabis Corp (NRTH) Click to Enlarge48North Cannabis Corp (TSE:NRTH) grows and sells medical marijuana.NRTH is also moving towards outdoor growing. The company announced last week that it successfully completed the planting of its first outdoor cannabis crop. This was at their 100-acre farm in Bryant County, Ont.This farm has 3.7 million square feet of growing space and the ability to yield over 100,000 pounds per harvest. That's a lot of weed. And its organic.I think that in addition to the cost savings, outdoor growing may have two other advantages as well. Some marijuana aficionados say that the best marijuana is grown in natural sunlight, so there may be an advantage in quality. * 7 Stocks to Buy This Summer Earnings Season The second advantage could be that growing in natural sunlight is socially conscious. The indoor growers need a tremendous amount of electricity for their operations and that results in pollution. Many customers of this industry are very concerned about climate change so this may affect their buying decisions. Cannabix Technologies Inc. (BLOZF) Click to EnlargeCannabix Technologies Inc. (OTCMKTS:BLOZF) develops and manufactures marijuana breathalyzers for the police. The stock symbol is pretty cool. BLOZ which is pronounced as blows. The F is added because it is a foreign company.I like idea behind Cannabix but I am not so sure that its future prospects are good. Unfortunately for BLOZF shareholders, the company has not turned a profit in the past 5 years. The stock just broke support at the 80 cents level. This level will now probably become a resistance level.Support becomes resistance because people who bought the stock at 80 cents are now losing money. They tell themselves that if it rallies back to 80, they will sell it. This sell interest creates the resistance level. Medipharm Labs Corp. (MEDIF) Click to EnlargeMedipharm Labs Corp. (OTCMKTS:MEDIF) is a medical cannabis company that focuses on downstream extraction and purification technologies.This company caught my attention due to the increased trading volume. This shows that maybe some of the bigger Walls Street funds or investors are getting involved.Medipharm just announced that it is moving from the Toronto Venture Exchange to the Toronto Stock Exchange. When a company moves its stock what is considered a higher tier exchange, such as in this case, it means that it will have more transparency and will make more disclosures. * 10 High-Flying, Overvalued Stocks in Danger of Crashing This is typically considered a bullish development for a company. Being on a higher tiered exchange gives it more credibility and makes it more appealing to investors. Neptune Wellness Solutions Inc. (NEPT) Click to EnlargeNeptune Wellness Solutions Inc. (NASDAQ:NEPT) engages in the extraction, purification, and formulation of cannabis products. This company caught my attention because it has been trending higher all year. Then yesterday, some positive news hit the tape.NEPT raised $41 million in a private placement. This means they issued new shares to private institutional investors in exchange for the cash. Shareholders must believe this is great news because the stock was up over 10% yesterday.Two Wall Street firms follow NEPT and they each have buy ratings on it. The average target price is $8.50. Valens Groworks Corp. (VGWCF) Click to EnlargeValens Groworks Corp. (OTCMKTS:VGWCF) is a biotechnology company that provides products which are developed from proprietary extraction techniques.This company has been trending higher since the beginning of the year. On July 15th, it released its second-quarter results. These showed that the company has made some significant improvements.Revenue increased to $8.8 million CAD. This was a 296% increase from the first quarter. Gross profit was $5.1 million CAD, which was 58% of revenue as compared to 38% for the first quarter. * 7 Defense Stocks to Buy to Fortify Your Portfolio Wall Street is very bullish on this stock. 4 firms follow it and they all have it rated as a buy. The average price target is $8.20, which is about 150% higher than current levels. PAO Group Inc. (PAOG) Click to EnlargePAO Group Inc. (OTCMKTS:PAOG) is a holding company which is dedicated to alternative patient care treatments.I have included this company to illustrate how some advertising in the financial media can be extremely mislead if not downright fraudulent.I am sure you have seen adds touting the recent alleged great performance of this or that recent recommendation. Ads that say thing like "this stock doubled" or "this stock is up 1,000%" are everywhere. Even though some of these headlines may technically be correct they can also be very misleading.For example, every stock has a bid and an offer. The bid is the highest price someone will pay for it and the offer is the lowest price someone will sell it for.Suppose a penny stock has a bid of 1 cent and an offer of 2 cents. If is someone sells it the last trade will be 1 cent. Then suppose some buys it. Now the last trade is 2 cents. The price has doubled, but the stock hasn't moved!Take a look at the PAOG price scale on the chart. This stock trades not in pennies but in ten thousandths of a penny. It could rise 1000% from 24 ten thousands to 240 ten thousandths. But there is no way you can make money. The trading costs would make it impossible to profit.So be careful when you see advertisements promoting supposed great returns. These returns may just be trading anomalies to are impossible to profit from.As of this writing the author held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Defense Stocks to Buy to Fortify Your Portfolio * 10 High-Flying, Overvalued Stocks in Danger of Crashing * 8 Stocks to Buy That Are Growing Faster Than Amazon The post 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk appeared first on InvestorPlace.
On July 23, the Banking, Housing and Urban Affairs Committee in the Republican-controlled Senate will discuss the challenges related to cannabis companies’ access to banking services. The hearing, titled “Challenges for Cannabis and Banking: Outside Perspectives” will feature testimony from a number of experts, including the Credit Union National Association, and sponsors and co-sponsors of the SAFE Banking Act bill. The second hearing, “Hemp Production and the 2018 Farm Bill,” will be held July 25 by the Senate Committee on Agriculture, Nutrition and Forestry, where members will hear testimony from representatives from the U.S. Department of Agriculture, Food and Drug Administration and the National Hemp Association, among others.
MediPharm Labs Corp. (OTC: MEDIF ), a company that specializes in research-driven cannabis extraction and cannabinoid isolation, announced Thursday that is has gained conditional authorization to uplist ...
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the Toronto Venture Exchange (“TSXV”) and list its common shares on the TSX under the symbol “LABS”. “We are thrilled to have qualified to uplist to the TSX. This is an important step for the MediPharm Labs team and our shareholders,” said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs.
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to provide an update to investors on the significant strategic progress it is making, including with its successful ramp up of production capacity to supply its growing customer base. Growing Private Label Volume & Forging White Label Platform: To date, MediPharm Labs has signed four large contracts including with Canopy Growth, Cronos Group and AusCann for the sale of private-label cannabis concentrate.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
NEW YORK , July 11, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the second quarter 2019 performance ...
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its wholly owned subsidiary, MediPharm Labs Inc., has entered into purchase agreements to secure a substantial 9,000 KG of dried cannabis supply from multiple cultivators in the last three weeks in June. In addition to MediPharm Labs’ ongoing procurement of cannabis biomass for existing contracts, this bulk purchase is expected to contribute to increased production for future sales and position the Company to meet the mandatory minimum monthly volume requirements to win new large white-label contracts. “With the increasing availability of bulk supply and our ongoing dried cannabis supply purchases, we are well positioned to significantly increase quarterly production over and above our existing contracts, which we expect to translate into additional sales from new white-label contracts that require substantial volumes monthly,” said Patrick McCutcheon, Chief Executive Officer of MediPharm Labs.
TORONTO, June 24, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis.
TORONTO, June 19, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis.
Medipharm Labs Corp (OTC: MEDIF ) said it applied to upgrade its stock to the Toronto Stock Exchange from the TSX Venture Exchange. MediPharm is a global extraction, distillation, purification and cannabinoid ...
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that the Company has applied to list its common shares on the Toronto Stock Exchange (“TSX”). Listing is subject to the approval of the TSX in accordance with its original listing requirements. The TSX has not conditionally approved the Company's listing application and there is no assurance that the TSX will approve the listing application.
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has closed its previously announced bought deal offering of 13,514,000 common shares in the capital of the Company (“Common Shares”) at a price of $5.55 per Common Share for aggregate gross proceeds of C$75,002,700 (the “Offering”). The Offering was underwritten by a syndicate of underwriters led by Scotia Capital Inc., GMP Securities L.P. and BMO Nesbitt Burns Inc. (collectively, the “Underwriters”).
Cronos Group (NASDAQ:CRON) has certainly lost its buzz. The company was the hottest name in marijuana just six months ago. After announcing its huge deal with Altria (NYSE:MO), the sky was the limit. CRON stock launched from $10 at the start of the year to as high as $25.Source: Shutterstock But the euphoria has waned. Shares skidded back to $15 earlier this year and have traded sideways for the past two months.It seems that a lot of folks are giving up on CRON stock. With more dealmaking and exciting happenings going on in other pot stocks, it would appear that people are selling out of their Cronos in order to put money elsewhere. But is that the right reaction? I'd argue that while Cronos has had a bit of a quiet period lately, it's still one of the stronger picks for longer-term investors in the space.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What's the Story, Cronos?InvestorPlace contributor Vince Martin summarized CRON stock's problem well in his recent article. Martin explained that Cronos Group stock "lacks a compelling narrative." He shows that, in a complex and fast-changing market like marijuana, companies need to specialize -- have some claim to fame -- in order to maintain investor interest. He wrote: "A stock needs a succinct bull case, an elevator pitch so to speak. And most of the well-covered cannabis plays have that type of case." * 7 Bank Stocks to Leave in the Vault I agree fully with the premise. CRON stock is clearly losing some of its luster as investors shift to other marijuana plays that have more going on right now. As Martin notes, Cronos isn't particularly strong in any one segment of the market. Its production capacity isn't even in the top 10 in Canada. Its overseas brands aren't that strong. The company has all that Altria money, but it's not clear how it's going to put it to work yet. There is some guidance toward its long-term plans, but there's not a lot of specifics in the near-term for investors to get excited about. MediPharm Deal Signals a Change in DirectionEarlier in May, Cronos group announced a major partnership with MediPharm (OTCMKTS:MEDIF). Cronos will buy C$30 million in marijuana from MediPharm and pay the company an additional sum of money to handle some of the product processing as well.While this is clearly great news for MediPharm, the takeaway for Cronos is more nuanced. On the one hand, Cronos clearly isn't rushing the buildout of its own capacity; in theory, Cronos could have handled this production capacity on its own by constructing the Peace Naturals building Unit No. 4 faster.Instead, it seems that post-Altria deal, Cronos is more focused on its longer-term goals rather than boosting production rapidly today. Perhaps, like Tilray (NASDAQ:TLRY), Cronos has realized that simple marijuana production is never going to be an especially profitable venture. It's important to note that Altria makes its money off its brands and intellectual property rather than actually growing tobacco. Over time, profits in the marijuana industry will similarly shift from the farmers to the brand and technology owners.It's hard to say what exactly Cronos is aiming for, since it hasn't laid out a clear road map for investors. But it's not hard to imagine a future where Cronos leads the world in marijuana vaping. Vaping is clearly a top priority for Altria given its actions with Juul. Cronos stock will be worth multiples of what it is today if Altria is able to make Cronos the Juul of the marijuana space. CRON Stock VerdictCRON stock offers a classic test of investors' patience. For long-term investors, there are plenty of good reasons to like CRON stock as opposed to its marijuana rivals. For one thing, the company has a ton of cash and a strong backer. It doesn't need to move quickly. Taking time to deploy its capital in small doses, such as we see with the MediPharm Labs deal, gives it the opportunity to have a lot of shots on goal while the industry evolves. * 7 Stocks to Buy That Are Near 52-Week Highs But for people wanting a story that will play out in 2019, CRON stock doesn't have a lot of offer. As Martin so correctly states, most of the leading pot stocks have a clear, easy-to-understand narrative, or thesis, driving their strategy. Cronos, by contrast, is doing some of this and some of that, knowing that its alliance with Altria gives it plenty of time to execute on its plans.That may lead to CRON stock struggling in the short-term. But for longer-term holders, Cronos' more deliberate strategy may pay off, as other competitors that move too fast, fail to adapt to the rapidly changing marijuana market conditions.At the time of this writing, Ian Bezek owned MO stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right * 7 Bank Stocks to Leave in the Vault * 7 Stocks for You to Profit From (Legal) Insider Trading Compare Brokers The post Cronos Stock Is Interestinga¦ but Patience Is Required appeared first on InvestorPlace.
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that, due to strong demand, it has entered into a revised agreement with syndicate of underwriters led by Scotiabank, GMP Securities L.P. and BMO Capital Markets (collectively the “Underwriters”), to increase the size of its previously announced $60,023,250 “bought deal” offering. Pursuant to the upsized deal terms, the Underwriters have agreed to purchase, on a “bought deal” basis, an additional 2,699,000 common shares of the Company (“Common Shares”) at the same issue price of $5.55 per Common Share (the “Offering Price”) for aggregate gross proceeds of $75,002,700 (the “Offering”).
MediPharm Labs Corp. (TSXV: LABS) (OTC: MEDIF ), a company that specializes in research-driven cannabis extraction and cannabinoid isolation, on Tuesday announced an agreement with Bank of Nova Scotia ...
Today we'll evaluate Medicon Hellas S.A. (ATH:MEDIC) to determine whether it could have potential as an investment...
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by the Icahn School of Medicine at Mount Sinai Hospital, New York City (“Icahn School of Medicine”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by The Mount Sinai Hospital, New York City (“Mount Sinai”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its subsidiary, MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”), has received its cannabis manufacturing licence (the “Licence”) from the Australian Office of Drug Control under the Narcotics Drugs Act 1967 on May 21, 2019. This is a significant milestone for MediPharm Labs that establishes the Company as an early mover in the Australian cannabis industry. In addition, MediPharm Labs Australia is expected to provide the Company with a global supply chain platform and a foothold in the Asia-Pacific region.
TORONTO, May 21, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and.
VANCOUVER, British Columbia, May 17, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the.
MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”), has signed a committed term sheet for a $20 million senior secured revolving credit facility ("Credit Facility") from a Canadian Schedule 1 Bank. The Credit Facility is intended to provide MediPharm Labs access to non-dilutive capital to fund planned growth, as well as for general corporate and working capital purposes. The Credit Facility consists of a $15 million operating loan with a one-year term and a $5 million non-revolving equipment term loan with a three-year term. The Credit Facility, once closed, will bear interest at the Schedule 1 Bank’s prime lending rate plus 1.85% per annum.